The clinical value of PD-L1 status as predictive biomarker in first-line treatment of urothelial carcinoma of the bladder

被引：0
|
作者：
Tamalunas, A. [1 ]
Schott, M. [1 ]
Rodler, S. [1 ]
Stief, C. G. [1 ]
Casuscelli, J. [1 ]
机构：
[1] Univ Hosp Munich, Dept Urol, Munich, Germany
来源：
EUROPEAN UROLOGY | 2022年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1065
引用
收藏
页码：S1570 / S1570
页数：1
相关论文
共 50 条
  • [1] The vanishing clinical value of PD-L1 status as predictive biomarker in first-line treatment of urothelial carcinoma of the bladder
    Tamalunas, A.
    Goetz, M.
    Rodler, S.
    Stief, C. G.
    Casuscelli, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1345 - S1345
  • [2] The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder
    Tamalunas, Alexander
    Aydogdu, Can
    Unterrainer, Lena M.
    Schott, Melanie
    Rodler, Severin
    Ledderose, Stephan
    Schulz, Gerald B.
    Stief, Christian G.
    Casuscelli, Jozefina
    CANCERS, 2024, 16 (08)
  • [3] Advanced or metastatic Urothelial Carcinoma New First-line Strategy established with PD-L1 Inhibitor
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [4] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Prevalence of PD-L1 expression in first-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC).
    Grivas, Petros
    Morgans, Alicia K.
    Lotan, Yair
    Gregg, Jeffrey P.
    Geynisman, Daniel M.
    Friedlander, Terence W.
    Agarwal, Piyush K.
    Tesic-Schnell, Marija
    Bernstein, Andrew
    Makari, Doris
    Meeks, Joshua J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [6] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    MODERN PATHOLOGY, 2016, 29 : 272A - 272A
  • [7] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    LABORATORY INVESTIGATION, 2016, 96 : 272A - 272A
  • [8] Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
    Tosev, Georgi
    Wahafu, Wasilijiang
    Reimold, Philipp
    Damgov, Ivan
    Schwab, Constantin
    Aksoy, Cem
    Kaczorowski, Adam
    Stenzinger, Albrecht
    Nyarangi-Dix, Joanne
    Hohenfellner, Markus
    Duensing, Stefan
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
    E. El Rassy
    T. Assi
    Z. Bakouny
    N. Pavlidis
    J. Kattan
    Clinical and Translational Oncology, 2019, 21 : 280 - 288
  • [10] Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
    El Rassy, E.
    Assi, T.
    Bakouny, Z.
    Pavlidis, N.
    Kattan, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03): : 280 - 288
12345